Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (19)

2024

  1. Cáncer de pulmón

    Oncología clínica (Arán Ediciones), pp. 227-257

  2. Melanoma maligno

    Oncología clínica (Arán Ediciones), pp. 381-394

  3. Síndromes paraneoplásicos

    Oncología clínica (Arán Ediciones), pp. 189-202

  4. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

    Cancers, Vol. 15, Núm. 17

  2. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

2022

  1. Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review

    Current Problems in Cancer: Case Reports, Vol. 6

  2. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  3. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Autoimmune responses in oncology: Causes and significance

    International Journal of Molecular Sciences, Vol. 22, Núm. 15

  2. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

    Nature Communications, Vol. 12, Núm. 1

  3. Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma

    Cancers, Vol. 13, Núm. 20

  4. Tracking the antibody immunome in sporadic colorectal cancer by using antigen self-assembled protein arrays

    Cancers, Vol. 13, Núm. 11

2019

  1. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS)

    Oncologist, Vol. 24, Núm. 6, pp. e338-e346

2007

  1. Antiangiogenesis and metastatic breast cancer: Bevacizumab

    Cancer and Chemotherapy Reviews, Vol. 2, Núm. 4, pp. 203-210

  2. Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients

    Cancer Letters, Vol. 255, Núm. 1, pp. 71-76

  3. Reversible posterior leukoencephalopathy syndrome induced by sunitinib [10]

    Journal of Clinical Oncology

2006

  1. Case 3. Upper limb lymphangiosarcoma following breast cancer therapy

    Journal of Clinical Oncology, Vol. 24, Núm. 9, pp. 1477-1478

2005

  1. Taponamiento cardíaco como forma de presentación de un tumor de origen desconocido: Abuso en las pruebas diagnósticas

    Oncologia, Vol. 28, Núm. 6, pp. 39-42